Adhering to the service tenet of "Integrity, Innovation, Harmony, and Win-win", We have established a complete one-stop procurement and comprehensive solution service system.
| RT5 | 5mg*10vials |
| RT10 | 10mg*10vials |
| RT15 | 15mg*10vials |
| RT20 | 20mg*10vials |
| RT30 | 30mg*10vials |
| RT60 | 60mg*10vials |
Retatrutide is an experimental drug developed by Eli Lilly and Company in the United States for the treatment of obesity. It is a triple glucagon hormone receptor agonist.
In a phase II clinical trial, the drug has been proved to reduce the average weight of non diabetes but obese or pre obese (overweight) adults by more than 17.5%
